US FDA Releases Slew Of Guidances On A Fell Day For Complex Generics
Executive Summary
New and updated guidances are good news for ANDA sponsors, but timing – coming the day Sandoz announced a CRL for its Advair copy – underscores challenges that developers of complex generics face.
You may also be interested in...
Teva Xtampza Settlement Brings Potential Three-Year Head Start
Teva is lining up another complex ANDA product after agreeing to settle litigation with Collegium Pharmaceutical over the Israeli firm’s proposed generic version of Xtampza ER (oxycodone) extended-release capsules.
Complex Generics Guidance: US FDA Aims To Alert Firms, As GAO Requested
The US FDA says it's working to provide the type of notice generic drug firms told the General Accountability Office they want to receive whenever the agency plans to issue or revise product-specific guidance on complex generics. Surprise issuance causes setbacks for generic drug sponsors who must scramble to revise their applications accordingly, if they can.
Hikma's CRL Proves GSK's Witty Was Right: Generic Advair Is Hard
FDA issued a complete response letter for Hikma's ANDA to market a generic version of GSK's Advair, the second application to be rejected by FDA.